Preoperative therapy for early-stage NSCLC: Opportunities and challenges

ONCOLOGY

Volumn 23, Issue 10, 2009, Pages

  Owonikoko, Taofeek K ^a   Khuri, Fadlo R ^a   Ramalingam, Suresh S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFINITOR; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EVEROLIMUS; PACLITAXEL; PAZOPANIB; PEMETREXED; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; COMORBIDITY; DOSE RESPONSE; DRUG MECHANISM; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL PRACTICE; MULTIPLE CYCLE TREATMENT; NOTE; RATING SCALE; TREATMENT OUTCOME; TUMOR BIOPSY;

EID: 72449198506     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Note

References (9)

1. Arriagada R, Bergman B, Dunant A, et al: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351-360, 2004. (Pubitemid 38101630)
2. Winton T, Livingston R, Johnson D, et al: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352:2589-2597, 2005. (Pubitemid 41007845)
3. Pignon JP, Tribodet H, Scagliotti GV, et al: Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol 26:3552-3559, 2008.
4. Pisters KM, Vallieres E, Bunn PA, et al: S9900: Surgery alone or surgery plus induction (ind) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Follow-up on a phase III trial (abstract 7520). J Clin Oncol 25(18S):389s, 2007.
5. Nikolinakos P, Altorki N, Guarino M, et al: Analyses of plasma cytokine/angiogenic factors (C/AFs) profile during preoperative treatment with pazopanib (GW786034) in early-stage non-small cell lung cancer (abstract 7568). J Clin Oncol 26(15S):414s, 2008.
6. Felip E, Massuti B, Alonso G, et al: Surgery (S) alone, preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy followed by S, or S followed by adjuvant (adj) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Results of the NATCH multicenter, randomized phase III trial (abstract 7500). J Clin Oncol 27(15S):382s, 2009.
7. Alberola V, Camps C, Provencio M, et al: Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: A Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 21:3207-3213, 2003.
8. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008.
9. Zheng Z, Chen T, Li X, et al: DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356:800-808, 2007. (Pubitemid 46294612)